Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial is a paper indexed in PICO Portal from OpenAlex.
How many citations does Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial have?
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial has 94 citations in the OpenAlex counts PICO Portal stores.
When was Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial published?
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial has 2023 year in the PICO Portal index.
What is the open-access status of Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial?
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial has hybrid oa status in the PICO Portal index.
What is the DOI of Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial?
The DOI for Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial is on the source record.
What is the PMID of Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial?
The PMID for Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial is on the source record.
What is the OpenAlex record for Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial?
The OpenAlex for Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial is on the source record.